CompletedPhase 3NCT01951924
LIME Study (LFB IVIg MMN Efficacy Study)
Studying Generalized bulbospinal muscular atrophy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Laboratoire français de Fractionnement et de Biotechnologies
- Principal Investigator
- Jean-Marc LEGER, MDHôpital de la Pitié Salpêtrière - Paris 75013
- Intervention
- Biological : I10E (Human normal Immunoglobulin for intravenous administration 100mg/mL)(drug)
- Enrollment
- 23 target
- Eligibility
- 18-80 years · All sexes
- Timeline
- 2013 – 2016
Study locations (18)
- CHU de Bordeaux -Hôpital Haut-Lévêque, Bordeaux, France
- CHU Créteil - Groupe Hospitalier Henri Mondor, Créteil, France
- CHRU Lille - Hôpital Roger Salengro, Lille, France
- CHU de Lyon - Hôpital Pierre Wertheimer, Lyon, France
- CHU de Marseille - Hôpital de La Timone, Marseille, France
- CHU de Nice - Hôpital l'Archet, Nice, France
- CHU Paris - Hôpital Pitié Salpétrière, Paris, France
- CHU de Saint Etienne - Hôpital Nord, Saint-Etienne, France
- Università di Genova - Ospedale San Martino, Genova, Italy
- IRCCS Istituto Clinico Humanitas, Milan, Italy
- Università Cattolica del Sacro Cuore, Roma, Italy
- Azienda Ospedaliero Universitaria San Giovanni Battista, Turin, Italy
- Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
- Hospital Clinico Universitario de Santiago de Compostela, Santiago de Compostela, Spain
- Hospital Universitario Virgen del Rocio, Seville, Spain
- +3 more locations on ClinicalTrials.gov
Collaborators
TFS Trial Form Support
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01951924 on ClinicalTrials.gov